Previous close | 32.81 |
Open | 32.86 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 32.48 - 33.09 |
52-week range | 32.48 - 48.28 |
Volume | |
Avg. volume | 89,284 |
Market cap | 2.293B |
Beta (5Y monthly) | 0.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.39 |
Earnings date | 02 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 46.50 |
Dynavax Technologies (DVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.